Andrii Buvailo, Ph.D.

<start of post>

Everyone is talking about the "Napster moment" for drug discovery, but they are missing the most important part of the story.

Last night, I was looking at the latest data from the AlphaFold 3 release and comparing it to the surge in "agentic" biotech startups we've seen in Q1. The hype is focused on the models. The reality is focused on the plumbing.

We are seeing a massive bifurcation in the industry. On one side, you have the "Design Layer"—the protein folding, the target ID, the molecular docking. This is commoditizing faster than anyone predicted. If a kid in a dorm can run a virtual screen for $46, your proprietary library isn't the moat you think it is.

On the other side, you have the "Physical Layer."

Manufacturing, clinical site recruitment, regulatory filings, and cold-chain logistics. This part is not getting cheaper. In fact, as the number of AI-designed candidates explodes, the bottleneck at the clinical stage is only getting tighter.

I've said this before and I'll say it again.. AI doesn't solve biology, it just moves the problem downstream.

Think about Eli Lilly. They didn't just buy AI startups; they built "digital twins" of their factories. They realized that making the drug is currently more valuable than finding the drug.

The next decade of "AI Bio" won't be won by the best model. It will be won by the company that integrates that model into a boring, unglamorous, and highly efficient physical execution engine.

The moonshots are exciting, but the infrastructure is where the money is.

What do you think? Are we over-indexing on "discovery" while ignoring the "delivery" bottleneck?

#biotech #ai #drugdiscovery

<end of post>